James N. Ingle

Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol

Background. This study was designed to evaluate the prognostic importance of c‐erbB2 overexpression in a standardized cohort of patients with axillary lymph node positive breast cancer.

Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node‐positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors

Background. This analysis was conducted to evaluate the impact of selected clinical, histopathologic, and flow cytometric factors on sites of initial tumor relapse after postmastectomy adjuvant systemic therapy.

A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma.

This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m2 by 3‐hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first‐line therapy for women with metastatic breast carcinoma.

A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma

Tamoxifen (TAM) is generally considered the hormonal agent of choice for postmenopausal women with hormone receptor positive breast carcinoma. The somatostatin analogues, including octreotide, have demonstrated inhibition of breast carcinoma cell lines and multiple endocrinologic actions, including reduction of insulin‐like growth factor I (IGF‐I), a potent mitogen for breast carcinoma cells. In an attempt to improve the efficacy of TAM, this randomized trial was performed.

A Randomized Phase II Trial of Two Dosage Levels of Letrozole as Third-Line Hormonal Therapy for Women with Metastatic Breast Carcinoma

It is common practice to utilize a series of different hormonal agents in the treatment of postmenopausal women who, despite disease progression, continue to be candidates for hormonal therapy on a clinical basis. Letrozole is a new highly selective and potent aromatase inhibitor. There are limited data on third‐line hormonal therapy in general, and this study was undertaken to evaluate letrozole in this context.

Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials

The measurement of estrogen receptors (ER) in breast cancer specimens has traditionally been assessed with a dextran‐coated charcoal assay (DCCA). More recently the immunohistochemical staining (IHC) method has gained increasing popularity because of its ability to use fixed tissue, assess needle biopsies, and reduce cost. Controversy exists over the accuracy of IHC compared with that of DCCA in determining ER. We compared these two techniques using tumor tissue obtained from a large group of females with lymph node positive breast carcinoma with long term follow‐up.

Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: An analysis of patients entered on four prospective clinical trials

Information regarding prognostic factors and survival in elderly women with metastatic breast cancer treated with tamoxifen is limited.

Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer

Background. The fraction of breast cancer cells undergoing DNA synthesis at any one time is relatively low, which is problematic because most chemotherapeutic agents are most effective against dividing cells. Estrogens administered in vitro and in vivo can increase breast cancer cell proliferation. A randomized clinical trial was performed to determine if estrogenic recruitment could increase the effectiveness of combination chemotherapy.

A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma

This prospective trialiu was conducted to evaluate the outcome of patients treated with preoperative and postoperative chemotherapy, mastectomy, and irradiation for locoregionally advanced breast carcinoma.